Cutting-Edge PET/CT Scanner Is Clinically Operational

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

The world’s first clinically operational molecular imager with lutetium oxyorthosilicate (LSO) technology-the biograph LSO, manufactured by Siemens Medical Solutions-has produced a precisely registered, combined positron-emission tomography (PET)/computed tomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. The biograph LSO imager uses the high-speed properties of LSO as the PET scintillator to provide shorter scan times and unmatched patient throughput.

The world’s first clinicallyoperational molecular imager with lutetium oxyorthosilicate (LSO) technology—thebiograph LSO, manufactured by Siemens Medical Solutions—has produced aprecisely registered, combined positron-emission tomography (PET)/computedtomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. Thebiograph LSO imager uses the high-speed properties of LSO as the PETscintillator to provide shorter scan times and unmatched patient throughput.

The biograph LSO merges three components—the ECAT ACCEL PETscanner, the SOMATOM Emotion spiral CT scanner, and syngo multimodality software—intoa powerful scanning device that creates a precisely registered molecular imagein 15 minutes or less. The resulting image makes it possible for oncologists andother health-care providers to view detailed anatomy and the biologicalprocesses of internal organs and living tissue at the molecular level in asingle, noninvasive diagnostic procedure.

In addition to the biograph LSO, the biograph is available with bismuthgermanate (BGO) crystal technology—a proven and economic scintillator forquality high-resolution PET imaging. The first commercial installation of thebiograph with BGO technology was completed last fall at Memorial Sloan-KetteringCancer Center in Manhattan.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.